Hedge Funds Are Betting On Regeneron Pharmaceuticals Inc (REGN)

As one would reasonably expect, key hedge funds were leading the bulls’ herd. Two Sigma Advisors assembled the most valuable position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Two Sigma Advisors had $106.7 million invested in the company at the end of the quarter. Matthew Hulsizer’s PEAK6 Capital Management also initiated a $27.6 million position during the quarter. The other funds with brand new Regeneron Pharmaceuticals Inc (NASDAQ:REGN) positions are Peter Muller’s PDT Partners, Paul Marshall and Ian Wace’s Marshall Wace LLP, and Krishen Sud’s Sivik Global Healthcare.

Let’s now take a look at hedge fund activity in other stocks – not necessarily in the same industry as Regeneron Pharmaceuticals Inc (NASDAQ:REGN) but similarly valued. These stocks are The TJX Companies, Inc. (NYSE:TJX), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), General Motors Company (NYSE:GM), and EMC Corporation (NYSE:EMC). This group of stocks’ market values is similar to Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s market value.

As you can see, these stocks had an average of 65 hedge funds with bullish positions and the average amount invested in these stocks was $4.19 billion. That figure was $1.05 billion in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s case. General Motors Company (NYSE:GM) is the most popular stock in this table. On the other hand, The TJX Companies, Inc. (NYSE:TJX) is the least popular one with only 37 bullish hedge fund positions. Compared to these stocks, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is even less popular than The TJX Companies, Inc. (NYSE:TJX). Considering that hedge funds aren’t fond of this stock in relation to other companies analyzed in this article, it may be a good idea to analyze it in detail and understand why the smart money isn’t behind this stock. This isn’t necessarily bad news. Although it is possible that hedge funds may think the stock is overpriced and view the stock as a short candidate, they may not be very familiar with the bullish thesis. In either case, more research is warranted.